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ABSTRACT
Background: Neutrophil elastase (NE) has been linked to lung neutrophil dysfunction in bronchiectasis
and cystic fibrosis (CF), making NE inhibition a potential therapeutic target. NE inhibitor trials have given
mixed result perhaps because not all patients have elevated airway NE activity.
Methods: We tested whether a single baseline sputum NE measurement or a combination of clinical
parameters could enrich patient populations with elevated NE activity for “personalised medicine”. Intra-
and interindividual variations of total and active NE levels in induced sputum from patients with CF or
bronchiectasis were monitored over 14 days. Patients with established CF and bronchiectasis (n=5 per
group) were recruited. NE was measured using three different methods: one total and two active NE
assays. Subsequently, we analysed the association between clinical parameters and NE from a large
bronchiectasis cohort study (n=381).
Results: All three assays showed a high degree of day-to-day variability (0–233% over 14 days). There were
strong correlations found between all assays (p<0.0001). Despite high day-to-day variability, patients could
be stratified into “high” or “low” groups based on moderate cut-off levels. In the bronchiectasis cohort
study, factors most associated with high sputum NE levels were: Pseudomonas aeruginosa infection
(β-estimate 11.5, 95% CI −6.0–29.0), sputum colour (β-estimate 10.4, 95% CI 4.3–16.6), Medical Research
Council dyspnoea score (β-estimate 6.4, 95% CI 1.4–11.4) and exacerbation history (β-estimate 3.4, 95% CI
1.4–5.3). Collectively, P. aeruginosa infection, sputum colour and exacerbation frequency provided the
greatest specificity for “high” NE (98.7%, 95% CI 7.0–99.6%).
Conclusion: These results show that patients with bronchiectasis and CF can be effectively divided into
“high” or “low” groups, based on sputum NE assays or clinical inclusion criteria.
@ERSpublications
NE at baseline can enrich studies for “high” NE patients, while in bronchiectasis, inclusion of
patients with Pseudomonas aeruginosa, purulent sputum and frequent exacerbations provides a
high degree of certainty of including patients with high NE http://ow.ly/mPTS30nI8ec
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ORIGINAL ARTICLE
BRONCHIECTASIS
Introduction
Bronchiectasis is a chronic disease characterised by cough, sputum production, neutrophilic airway
inflammation and bacterial infection [1–3]. Bronchiectasis is a heterogeneous disease, being caused by a
range of disorders including cystic fibrosis (CF) and presenting with a wide spectrum of clinical
phenotypes [2, 4, 5].
Development of new treatments for bronchiectasis is essential in view of the high burden of the disease [6, 7].
Such development has been highly challenging and several randomised clinical trials in bronchiectasis have
failed to reach their primary end-points [8–11]. The difficulty in achieving positive results in bronchiectasis
trials is thought to be due to disease heterogeneity, arguing for a personalised or stratified medicine
approach [3]. Neutrophil elastase (NE) has long been implicated in the pathophysiology of bronchiectasis
[12–14]. NE inhibition is considered a promising therapeutic approach in bronchiectasis and CF [15].
In a study of 381 patients with bronchiectasis, NE activity was predictive of future risk of exacerbations
and lung function decline over 4 years [16]. This study, however, identified that a third of the cohort (132
out of 381 subjects) did not have detectable sputum NE activity [16].
NE inhibition is likely to only be an effective therapy in individuals with active NE in the airways [17–19].
The high frequency of individuals without significantly elevated NE may help to explain the mixed results
of prior studies of inhibitors [20, 21]. AZD9668 was tested in 38 patients with bronchiectasis. The primary
outcome of reducing sputum neutrophils was not met, but there was a significant 100 mL increase in
forced expiratory volume in 1 s (FEV1) and a trend to improvement in St George’s Respiratory
Questionnaire score [20]. A study of 94 patients with BAY85-8501 also showed no evidence of efficacy [21].
These studies did not enrich for patients with elevated sputum NE either using biomarkers or clinical
characteristics. There are a number of examples in respiratory medicine where drugs that were thought to
be ineffective were shown to be effective when targeted to the appropriate patient population using
biomarkers or clinical parameters [22, 23].
The aims of our study were: 1) to determine if sputum NE activity was stable over time to establish if it
could be used for population enrichment in clinical trials of NE inhibition, 2) to compare different assays
and sample types to identify the optimal method for enriching a clinical trial population, and 3) to study
the association of clinical parameters and baseline NE to identify the optimal inclusion criteria for a future
trial.
Methods
In the first part of the study we aimed to determine the optimal patient population for a future stratified
clinical trial, defined as patients with consistently elevated sputum NE levels.
This study enrolled 10 bronchiectasis and CF patients (n=5 per group) at Ninewells Hospital (Dundee,
UK). All patients were adults aged ⩾18 years and were clinically stable at the time of recruitment, defined
by the absence of acute antibiotic treatment for at least 4 weeks and the absence of exacerbation symptoms
at the screening visit. Both groups were required to have daily sputum production and be able to produce
sputum at screening. Exclusion criteria for both groups were: inability to give informed consent,
immunodeficiency, active mycobacterial infection, current smoker/ex-smoker of <1 year, active allergic
bronchopulmonary aspergillosis (ABPA), pregnancy/breastfeeding, long-term oxygen therapy and FEV1
<25% predicted. Specific inclusion criteria for CF subjects were: a diagnosis of CF with two
disease-causing CF transmembrane conductance regulator mutations. Specific inclusion criteria for
bronchiectasis subjects were: idiopathic or post-infective bronchiectasis confirmed on computed
tomography (CT). Exclusion criteria were: active sarcoidosis, α1-antitrypsin deficiency, poorly controlled
asthma and active malignancy. The study was approved by the local research ethics committee (16/ES/
0047) and all patients provided written informed consent.
Sputum was induced using 3% hypertonic saline for up to 20 min. Samples of sputum were obtained on
days 1 (baseline), 3, 5, 7 and 14 after enrolment. 24 h sputum collection was conducted on days 2–3, 4–5,
6–7 and 13–14 for measurement of 24 h sputum NE.
Availability of data and materials
Access to data held by the European Bronchiectasis Registry can be accessed through: www.bronchiectasis.
eu/dataaccess.
NE measurement
Sputum samples were processed through dilution with 8 times volume PBS followed by centrifugation at
3000×g for 15 min. The repeatability of three different NE assays was tested: 1) an activity-based
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fluorescence resonance energy transfer (FRET) assay according to the protocol of KORKMAZ et al. [24],
2) an activity-based immunoassay (ProteaseTag ELISA; ProAxsis, Belfast, UK) [25] and 3) a total NE
ELISA (AssayMax; Assaypro, St Charles, MO, USA), which measures total protein rather than activity. For
the FRET assay, the intra-assay coefficient of variation was 5.6% and the interassay coefficient of variation
was 8.8%. For the total NE assay, the intra-assay coefficient of variation was 14.5% and interassay
coefficient of variation was 10.6%. For the activity-based immunoassay, the intra-assay coefficient of
variation was 7.1% and interassay coefficient of variation was 7%.
Bronchiectasis cohort study
The objective of this analysis was to determine in a large patient cohort whether combinations of clinical
parameters (inclusion criteria for a hypothetical trial) could be used to identify patients with elevated
sputum NE using the ProteaseTag immunoassay.
Patients were recruited to a longitudinal observational study (the TAYBRIDGE registry) at Ninewells
Hospital [26]. The study was approved by the local research ethics committee (12/ES/0059) and all
patients gave written informed consent. Inclusion criteria were: age ⩾18 years, high-resolution
CT-confirmed bronchiectasis and clinical symptoms consistent with bronchiectasis. Exclusion criteria
were: inability to give informed consent, active mycobacterial infection, active ABPA, malignancy, CF or
pulmonary fibrosis with traction bronchiectasis.
Baseline data were used to evaluate the association of sputum NE concentration and clinical parameters.
Severity of disease was evaluated with the Bronchiectasis Severity Index (BSI) [27]. Chronic bacterial
infection was defined as the growth of pathogens from sputum on at least two occasions 3 months apart
during the previous 12 months [28]. Exacerbation frequency was defined according to British Thoracic
Society criteria [29, 30].
Statistical analysis
Repeatability statistics used were the coefficient of variation and the within-subject standard deviation.
Mean differences between groups were compared with the t-test. Correlations utilised linear regression. For
predictive tests we calculated sensitivity, specificity and positive/negative predictive values. To identify
clinical parameters associated with sputum NE we used a multiple linear regression with sputum NE as a
linear dependent variable. We used 20 µg·mL−1 as a pre-defined cut-off of “high” NE based on our prior
work [11]. A sensitivity analysis was performed looking at predictive statistics for cut-offs defined by the
lower and upper 95% confidence intervals of the biomarker distribution. For analysis of clinical
characteristics associated with NE, a multivariable logistic regression with a binary dependent variable of
NE >20 µg·mL−1 was used in this analysis, with an exploratory analysis using a higher cut-off of
50 µg·mL−1. p<0.05 was considered statistically significant.
Results
Repeatability of sputum NE as a biomarker (CF and bronchiectasis)
The characteristics of the five patients with bronchiectasis and five patients with CF are shown in
supplementary tables S1 and S2. Patients with bronchiectasis were predominantly elderly, three were
treated with chronic macrolide therapy and four were never-smokers. FEV1 ranged from 45% to 110%
predicted. Using the BSI, two patients were classified as severe, two were moderate and one was mild.
The adult CF patients had an age range of 21–38 years and had 0–6 exacerbations per year. The majority
were receiving prophylactic oral antibiotic therapy.
Repeatability of sputum NE quantification
To investigate whether a single “point-of-care” or laboratory measurement of sputum NE could be used
for stratification in a trial we examined whether a single measure in induced or 24 h sputum could identify
patients with consistently high or low levels of sputum NE.
The repeatability data are shown in figure 1 for each assay. All of the assays showed a high degree of
day-to-day variability. No patients had exacerbations or changes in clinical status during the study to
explain these changes. We observed no benefit of 24 h sputum collections, in terms of reducing variability,
compared with a single-point induced sputum.
Figure 2 shows the median coefficient of variation per subject. NE values from visit to visit varied by 0%
to 233% within individuals. 0% refers to one individual with undetectable NE activity using the FRET
active NE assay at each time-point. This individual was excluded in calculating the variability of the assay.
There was no clear difference in repeatability between bronchiectasis and CF.
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Despite the high variability observed there was a distinction between “high” and “low” patients as defined
by sputum NE. A previous publication using the ProteaseTag immunoassay defined “high” as >20 µg·mL−1
as this cut-off was associated with clinical outcomes [11]. Based on the strong correlation between the
three assays (figure 3) we determined that 176 µg·mL−1 using the total NE ELISA and 138 µg·mL−1 using
the FRET NE assay correspond to the 20 µg·mL−1 cut-off for which clinical data were available.
All subjects with NE levels <20 µg·mL−1 continued to have levels <20 µg·mL−1 at follow-up. This was used
to generate predictive statistics as shown in table 1. In addition, predictive statistics are shown to identify
patients above the lower and upper 95% confidence intervals for each assay. Across the whole population
the mean levels were: total NE 271.3 µg·mL−1 (95% CI 180–362.6 µg·mL−1), FRET active NE 267 µg·mL−1
(95% CI 130.9–404.4 µg·mL−1) and active NE 36.9 µg·mL−1 (95% CI 16.9–56.9 µg·mL−1).
These data suggest that NE measurement can effectively exclude patients likely to rarely have elevated NE,
which may be useful for stratification in clinical trials.
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FIGURE 1 Day-to-day variability in the measurement of sputum neutrophil elastase (NE) measured using
three different assays at the same time-points: a, b) fluorescence resonance energy transfer (FRET) active
NE, c, d) active NE (ProteaseTag) and e, f ) total NE. Open symbols: individual cystic fibrosis subjects (n=5);
solid symbols: individual bronchiectasis subjects (n=5). a, c, e) Induced sputum samples taken at days 1, 3, 5,
7 and 14 post-enrolment. b, d, f ) 24 h sputum collections commencing on days 2, 4, 6 and 13 and completed
on days 3, 5, 7 and 14.
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Clinical parameters to select patients for a randomised controlled trial of NE inhibition
This analysis included 381 patients with bronchiectasis. Median (interquartile range) age was 67
(58–74) years and FEV1 was 71.4% (49.4–90.9%) predicted. The median exacerbation frequency was 1 per
year. 60 patients (15.7%) were chronically infected with P. aeruginosa.
Based on the prior results, two candidate cut-offs were identified for elevated sputum NE for inclusion in
a stratified trial: high (>20 µg·mL−1) and very high (>50 µg·mL−1). Logistic regression analysis of
predictors of these NE levels is shown in table 2.
Across all of these analyses, there was a consistent trend that purulent sputum colour, elevated Medical
Research Council (MRC) dyspnoea score, more extensive radiological bronchiectasis and exacerbation
frequency were associated with elevated NE activity, independent of other variables. P. aeruginosa infection
also appeared to be strongly associated with elevated NE, but was nonsignificant in most models.
Based on the aforementioned analysis we generated a set of potential inclusion criteria approaches for
clinical trials, and evaluated their sensitivity and specificity. As a guide to interpretation of the data, a high
specificity indicates a low likelihood of including patients without NE >20 µg·mL−1 in a trial, which is
desirable. A low sensitivity, however, indicates that a large number of individuals who could potentially
benefit from therapy (because of elevated NE >20 µg·mL−1) would be excluded using these inclusion
criteria. Our results suggest that stratifying on sputum colour provided the greatest degree of sensitivity, as
only 6.7% of subjects had NE >20 µg·mL−1 with a sputum sample graded as mucoid, while P. aeruginosa
infection provided high specificity as a single criterion. The results for various combinations of criteria are
shown in table 3.
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FIGURE 2 Coefficient of variation within subjects for each neutrophil elastase (NE) assay: total NE, active NE (ProteaseTag) and fluorescence
resonance energy transfer (FRET) active NE. a) Bronchiectasis, b) cystic fibrosis and c) both populations combined. Plots show median with
interquartile range (boxes) and range (whiskers). One subject with undetectable FRET NE activity (and therefore 0% variation) at all time-points
was not included in calculating the coefficient of variation.
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FIGURE 3 Intercorrelation between different neutrophil elastase (NE) assays in subjects with bronchiectasis and cystic fibrosis. FRET:
fluorescence resonance energy transfer. a) FRET active NE versus total NE, b) active NE (ProteaseTag) versus total NE and c) active NE
(ProteaseTag) versus FRET active NE.
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Discussion
This aim of this study was to support the future development of NE inhibitors for the treatment of patients
with bronchiectasis and CF by providing data to identify the patient population most likely to benefit
from treatment. This concept of precision medicine is increasingly advocated across respiratory medicine,
and has led to significant progress in areas such as cancer and severe asthma [31–34]. Bronchiectasis is a
heterogeneous disease with multiple phenotypes/endotypes [2, 3, 35]. NE is thought to play a key
pathophysiological role, but is not consistently elevated in all patients [16]. Inclusion of a relatively
unselected group of patients with bronchiectasis would therefore not be expected to result in positive results,
TABLE 1 Predictive statistics for the ability of a single baseline induced sputum measurement
of neutrophil elastase (NE) (activity or total protein as indicated) to predict a NE measurement
above the predefined threshold at follow-up or at any stage during the study
Outcome and test Sensitivity % Specificity % PPV % NPV %
“High” NE at day 14
FRET active NE 100 100 100 100
Active NE (ProteaseTag) 100 75 50 100
Total NE ELISA 100 85.7 75 100
“High” NE at any time-point
FRET active NE 66.7 100 100 66.7
Active NE (ProteaseTag) 80 100 100 83.3
Total NE ELISA 66.7 100 100 66.7
Above lower 95% CI at day 14
FRET active NE 100 85.7 75 100
Active NE (ProteaseTag) 100 75 50 100
Total NE ELISA 100 85.7 75 100
Above lower 95% CI at any time-point
FRET active NE 80 100 100 83.3
Active NE (ProteaseTag) 80 100 100 83.3
Total NE ELISA 60 80 75 66.7
Above upper 95% CI at day 14
FRET active NE 100 100 100 100
Active NE (ProteaseTag) 100 88.9 50 100
Total NE ELISA 100 100 100 100
Above upper 95% CI at any time-point
FRET active NE 66.7 100 100 87.5
Active NE (ProteaseTag) 100 100 100 100
Total NE ELISA 100 87.5 66.7 100
PPV: positive predictive value; NPV: negative predictive value; FRET: fluorescence resonance energy
transfer.
TABLE 2 Multivariable analysis of determinants of neutrophil elastase (NE) activity in bronchiectasis
Linear regression analysis Logistic regression
analysis to predict sputum
NE >20 µg·mL−1
Logistic regression
analysis to predict sputum
NE >50 µg·mL−1
β-estimate (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Pseudomonas aeruginosa infection 11.5 (−6.0–29.0) 0.2 2.17 (0.88–5.33) 0.09 0.98 (0.28–3.38) 0.9
Sputum colour (4-point scale) 10.4 (4.3–16.6) 0.001 2.13 (1.50–3.03) <0.0001 2.80 (1.70–4.62) <0.0001
MRC dyspnoea score 6.4 (1.4–11.4) 0.01 1.57 (1.18–2.09) 0.002 2.43 (1.56–3.78) <0.0001
Exacerbation history (per 1 event) 3.4 (1.4–5.3) 0.001 1.07 (0.96–1.19) 0.2 1.16 (1.02–1.32) 0.03
Radiological extent (per additional lobe) 1.5 (0.1–2.9) 0.03 1.12 (1.05–1.21) 0.002 1.09 (0.98–1.20) 0.1
Male 1.1 (−8.5–10.6) 0.8 0.82 (0.40–1.45) 0.5 0.61 (0.27–1.40) 0.2
Infection with other organisms 0.4 (−10.6–11.4) 0.9 1.23 (0.61–2.46) 0.6 0.69 (0.22–2.16) 0.5
Age (per year) 0.1 (−0.3–0.5) 0.7 1.01 (0.99–1.04) 0.4 1.01 (0.98–1.05) 0.5
FEV1 % pred −0.1 (−0.3–0.1) 0.3 0.98 (0.97–1.00) 0.05 0.99 (0.98–1.01) 0.5
MRC: Medical Research Council; FEV1: forced expiratory volume in 1 s.
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assuming that NE inhibition is not beneficial in patients without NE activity in sputum. We think this is a
reasonable assumption, and is supported by unsuccessful clinical trials of NE inhibitors in unselected
populations with bronchiectasis and chronic obstructive pulmonary disease (COPD) to date [20, 36–38].
In this study we examined questions for the design of future NE inhibitor trials. First, whether NE activity
is stable over time, and therefore whether patients can be grouped into “high” and “low” groups with the
aim of including only patients with high NE. We examined this by measuring longitudinal NE levels on
five occasions over 14 days while clinically stable. This approach removed possible biases induced by
antibiotic treatment, which is known to reduce NE, and the impact of new treatments by conducting
measurements over a carefully controlled time period. Our results showed high day-to-day variability, with
>200% variation over 14 days in some patients. Nevertheless, as an example, while a change in NE from
1152 to 2291 µg·mL−1 occurred in a subject with CF, which represents a high degree of variability, in
practical terms this patient has sustained high levels of NE activity at every time-point. Examining the data
in this way we showed high sensitivity and specificity for two active NE assays and one total NE ELISA to
identify patients’ longitudinal behaviour. This means that a single measurement of sputum NE in stable
patients could reliably be used to stratify patients for trial inclusion. We identified no advantage of 24 h
sputum collection over induced sputum sampling at a single time-point and so recommend the more
straightforward method of collection [39]. We acknowledge the limitation of this study’s small sample size,
but our recent results are supported by repeatability data from our previous study in 381 patients and
therefore we consider it highly unlikely a study with a larger sample size would find different results [16].
There may be practical reasons why using an NE assay at baseline to determine inclusion in a clinical trial
may be challenging. For a phase 3 trial with large numbers of subjects in particular, deploying and
standardising an assay across potentially hundreds of sites could be very difficult. We were therefore
interested to test whether clinical parameters could be used as a proxy for a “high” NE population. We
found that sputum colour, MRC dyspnoea score and presence of P. aeruginosa were the variables most
strongly associated with NE activity. These are not surprising, as the green colour of sputum is generated
by myeloperoxidase, a green protein which is co-released with NE from neutrophil azurophil granules
during degranulation or neutrophil extracellular trap formation [40–42]. P. aeruginosa is known to be a
potent neutrophil activator and acts as a stimulus for persistent neutrophil recruitment [43, 44]. Both have
previously been shown to be associated with elevated NE [45–47]. What is novel in our study is that we
can estimate using a large cohort of 381 patients, the likelihood of successfully targeting the right patient
population in a future trial. It is not as simple as suggesting that investigators should use one or other of
these criteria, but rather it would depend on the study design and study objectives.
For example, in a small proof-of-concept study such as those already conducted in bronchiectasis, it might
be important to ensure all patients had elevated NE so that a signal could be observed in a small number
of subjects. In this case, a high specificity would be important, and the investigators may wish to limit
enrolment to patients with P. aeruginosa infection (92% specificity in our data) or even P. aeruginosa plus
purulent sputum and a history of two or more exacerbations (98% specificity). However, for a large phase 3
trial with an NE inhibitor, a balance would be needed between specificity and the feasibility of enrolling
large numbers of subjects, and therefore different criteria with higher sensitivity may be used.
TABLE 3 Sensitivity/specificity of different combinations of inclusion criteria for a hypothetical trial of neutrophil elastase (NE)
inhibition aiming to enrol patients with >20 µg·mL−1 sputum NE activity at baseline
Sensitivity
(95% CI) %
Specificity
(95% CI) %
PPV
(95% CI) %
NPV
(95% CI) %
Sputum colour grade ⩾2 93.3 (86.6–97.3) 46.5 (41.4–51.6) 32.2 (29.9–34.6) 96.2 (92.5–98.1)
Sputum colour grade 3/4 only 58.7 (48.6–68.2) 79.1 (73.8–83.7) 51.3 (33.3–58.2) 83.6 (80.1–86.6)
P. aeruginosa patients only 37.5 (28.2–47.5) 92.4 (88.6–95.3) 65.0 (53.5–75.0) 79.8 (77.2–82.1)
P. aeruginosa+grade 3/4 sputum and a history of ⩾2 exacerbations
per year
24.0 (16.2–33.4) 98.7 (97.0–99.6) 83.3 (66.2–92.7) 82.6 (81.0–84.1)
Sputum colour grade ⩾2 and ⩾2 exacerbations per year 65.4 (55.4–74.5) 76.1 (71.5–80.3) 42.8 (37.3–48.4) 89.0 (86.0–91.3)
Sputum colour grade ⩾2, MRC dyspnoea score ⩾3, ⩾3 lobes
involved on CT and ⩾2 exacerbations per year
37.5 (28.2–47.5) 91.6 (88.4–94.2) 54.9 (44.6–64.8) 84.3 (82.2–86.2)
⩾3 exacerbations per year, ⩾2 lobes involved on CT and infection
with any organism (including P. aeruginosa)
16.4 (9.8–24.9) 91.3 (88.1–94.0) 34.0 (23.0–47.0) 80.0 (78.5–81.4)
PPV: positive predictive value; NPV: negative predictive value; P. aeruginosa: Pseudomonas aeruginosa; MRC: Medical Research Council; CT:
computed tomography.
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Our study has limitations which we acknowledge. We chose to study repeatability of NE in both
bronchiectasis and CF patients, but only focused the subsequent cohort analysis on bronchiectasis based
on our prior observation of a third of subjects having undetectable NE. A similar analysis is required for
CF. Mean NE activity is higher in adult CF than bronchiectasis and so the cut-offs used in our study
should not be extrapolated to CF or other conditions such as COPD [48, 49]. We used NE >20 µg·mL−1 as
a cut-off based on our prior publication [11], but we acknowledge that we cannot prove patients with
lower levels of NE would not benefit from NE inhibitors. Our study was conducted in a single region in
Scotland and so may not be generalisable, although we consider this unlikely given the high level of
similarity between our patient population and others across Europe [50].
Conclusion
We have shown that patients with bronchiectasis and CF can be effectively divided into those with
consistently elevated or lower levels of sputum NE using sputum NE assays or using clinical parameters.
This provides evidence that NE inhibitors could be targeted using a “precision medicine approach” in
patients with bronchiectasis and warrants further research in patients with CF.
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